MK-4541 

MK-4541 is an orally active and selective androgen receptor (AR) modulator. MK-4541 acts as an antagonist to inhibit 5α-reductase. MK-4541 inhibits proliferation and induces apoptosis in AR positive prostate cancer cells. MK-4541 significantly inhibited the growth of R3327-G prostate tumors in xenograft mouse model^[1].

MK-4541 (100 mg/kg; p.o.; 5 times per week for 5 weeks) inhibits prostate tumor growth in athymic nude mice bearing R-3327-G cells^[1].
MK-4541 (100 mg/kg, 200 mg/kg; p.o.; 5 times per week for 5 weeks) exhibits anti-androgen effects on the seminal vesicles, reduces plasma testosterone concentrations in intact males, and inhibits Ki67 expression^[1].
MK-4541 (15 mg/kg, 50 mg/kg; p.o.; 5 times per week for 8 weeks) causes the loss of musculoskeletal mass and function in adult castrated mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

428.49

C₂₂H₃₁F₃N₂O₃

796885-38-6

C[C@@]12[C@]3([H])[C@](CC[C@@]1([H])N(C(C=C2)=O)C)([H])[C@@]4([H])[C@@](C)([C@@H](NC(OCC(F)(F)F)=O)CC4)CC3

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Chisamore MJ, et al. A novel selective androgen receptor modulator (SARM) MK-4541 exerts anti-androgenic activity in the prostate cancer xenograft R-3327G and anabolic activity on skeletal muscle mass & function in castrated mice. J Steroid Biochem Mol Biol. 2016 Oct;163:88-97.  [Content Brief]